330
Participants
Start Date
March 31, 2007
Study Completion Date
November 30, 2007
PRX-00023
Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
Placebo for PRX-00023
Doses taken two times per day. dose increased at scheduled intervals from 40 mg to 80 mg to 120 mg.
University of Pennsylvannia, Philadelphia
GWU Clinical Psychiatric Research Center, Washington D.C.
Piedmont Neuropsychiatry, Charlotte
SE Health Consultants, LLC, Charleston
Atlanta Institute of Medicine and Research, Atlanta
CNS Healthcare of Jacksonville, Jacksonville
Chicago Research Center, Inc., Chicago
Vince and Associates Clinical Research, Overland Park
Brentwood Research Institute, Shreveport
University of Texas - Southwestern Medical Center, Dallas
R/D Clinical Research, Inc., Lake Jackson
Vista Medical Research, Inc., Mesa
AVI Clinical Research, Torrance
Pharmacology Research Institute, Los Alamitos
Pharmacology Research Institute, Encino
Pacific Clinical Research Medical Group, Upland
Synergy Clinical Research Center, National City
Excell Research, Oceanside
Pacific Clinical Research Medical Group, Riverside
Northwest Clinical Research Center, Bellevue
Summit Research Network, Seattle
Lead Sponsor
Epix Pharmaceuticals, Inc.
INDUSTRY